Clinical trial registry record

Safety and Efficacy Evaluation of LX111 Gene Therapy in nAMD Patients

A registered EARLY_PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Recruiting.
Evidence
Registered early phase 1 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated March 10, 2026.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT07053358
Last registry update
March 10, 2026
Status
Recruiting
Phase
EARLY Phase 1
Sponsor
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Enrollment
10
Countries
China
Match confidence
60%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered EARLY_PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
EARLY Phase 1
Study design
NA · SINGLE GROUP · TREATMENT · NONE
Evidence population
Human clinical study registration
Participants
10
Population
ALL · 50 Years
Duration
2025-07-02 to 2029-12-30
Intervention
LX111 Injection
Comparator
Not reported
Outcomes measured
Adverse events and serious adverse events in the eyes and throughout the body within 364 days after LX111 treatment — 5…; Dose Limiting Toxicity — 4 weeks; Mean changes in BCVA from Baseline — 12 weeks, 36 weeks, 52 weeks; Mean changes in Central Subfield Thickness (CST) from Baseline — 12 weeks, 36 weeks, 52 weeks; The percentage of subjects who received anti-VEGF supplemental injection within 52 weeks after LX111 treatment — 52 wee…
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · EARLY Phase 1A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 60% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 60%Source terminology contains: age-related macular degeneration. Source terminology supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 85%. These figures help sort records; they are not medical ratings.

vision aging
Open primary sourceExport JSON